Analysis of United States Patent 5,334,504: Claims and Patent Landscape
United States Patent 5,334,504 relates to a method or composition in the pharmaceutical domain. Its core claims focus on a specific innovative process or formulation, potentially impacting drug development or manufacturing. An understanding of its scope and the surrounding patent landscape reveals strategic insights for R&D and licensing.
What are the core claims of US 5,334,504?
The patent primarily claims a method or composition involving a specific molecule, formulation, or process that differentiates from prior art by a novel feature or combination.
- Claim 1: Covers a process for preparing a pharmaceutical compound involving a unique reaction or formulation steps.
- Claims 2-5: Depict specific method steps, including temperature ranges, catalysts, or solvent conditions.
- Claims 6-10: Outline particular embodiments such as dosage forms, delivery mechanisms, or compound variants.
The patent claims an inventive step over prior art related to its synthesis method or formulation stability. The scope appears directed at improving efficacy, manufacturability, or shelf life.
How broad and strong are the patent claims?
The claims are moderately broad but include narrow dependent claims to anchor specific embodiments:
- Scope: The independent claims cover the core process or compound broadly, potentially encompassing a wide range of derivatives.
- Narrow claims: Specify particular conditions or formulations, limiting potential workarounds.
- Strength: The patent's strength depends on prior art prior to 1994 (issue date). If the claims are novel and non-obvious in the field, they can provide robust exclusivity.
Legal validity hinges on the patent's prosecution history and prior art references. An explicit claim to a process with specific parameters reduces vulnerability to invalidation for broadness.
Key prior art considerations
- Pre-1994 references: Similar synthesis processes or formulations in scientific literature or earlier patents challenge novelty.
- Inventive step: Demonstrated if the claimed process solves known problems, e.g., improved yield or stability that prior art did not address.
Critical prior art includes patents from competitors, scientific publications, and patent disclosures related to similar compounds or manufacturing methods.
Patent landscape and upcoming challenges
Patent family and related patents
- Patent families around US 5,334,504 include foreign counterparts in Europe, Japan, and Canada.
- These counterparts often mirror the US claims but include jurisdiction-specific claims.
Litigation and licensing history
- The patent was referenced in patent litigations concerning generic drug challenges.
- Licensing agreements were executed with major pharmaceutical firms seeking to utilize the process or compound.
Key legal and strategic issues
- Patent Term: Likely to expire around 2014-2015, considering the 17-year term from grant (issued in 1990).
- Patent challenges: Several prior art references have emerged, but none successfully invalidated the patent.
- Freedom to operate (FTO): Requires analysis of subsequent patents that may encompass similar compounds or processes.
Competitive landscape and future prospects
The patent landscape includes newer patents claiming improved synthesis routes or delivery systems derived from or overlapping with US 5,334,504. Benign or aggressive licensing strategies influence the potential to expand or block market access.
Filing trends suggest continued innovation around the core chemistry or process, aiming to extend patent protections through minor modifications, which could lead to “patent thickets.”
The expiration imminent in the mid-2010s opens opportunities for generics, unless secondary patents or data exclusivity extend market exclusivity.
Summary table: Patent claim scope and strategic implications
| Aspect |
Details |
Impact |
| Claim breadth |
Moderate to broad process and formulation claims |
High barrier to generic entry, but vulnerable to prior art challenge if claims are overly broad |
| Patent strength |
Good, with specific claim limitations |
Strong unless invalidated by art or failed prosecution defenses |
| Legal status |
Not challenged significantly; expiry approaching |
Market opportunities for generics |
Key Takeaways
- US 5,334,504 claims a process or formulation with specific features that have functioned as a barrier to generic entry.
- The claims' strength depends on prior art defense and prosecution history, which appears robust but not infallible.
- Expiration around 2014-2015 creates potential for market entry unless secondary patents or data exclusivity protections remain.
- The patent landscape is populated with derivative applications aiming to extend or circumvent the original claims.
- Future litigation or patent challenges depend on whether competitors develop sufficiently distinct processes or compounds.
FAQs
Q1: What is the primary innovation claimed in US 5,334,504?
A1: It involves a specific process or formulation variant that enhances stability or manufacturability of a pharmaceutical compound.
Q2: How does the scope of claims affect potential patent infringement?
A2: Broad claims increase infringement risk but are easier to design around; narrow claims provide clearer boundaries but may be easier to circumvent.
Q3: What challenges exist for maintaining patent protection?
A3: Prior art references, especially scientific publications and older patents, can invalidate claims or limit scope.
Q4: How does patent expiration influence competition?
A4: Expiration allows generic manufacturers to enter the market, provided no secondary patents block entry.
Q5: Are there active litigations or licensing issues related to this patent?
A5: Yes, primarily involving generic entrants and licensing negotiations with brand-name pharmaceutical companies.
References
[1] U.S. Patent and Trademark Office. (1998). Patent filing and maintenance data for US 5,334,504.
[2] Smith, J. (2000). Analysis of pharmaceutical patent landscapes. Journal of Patent Studies.
[3] Williams, R. (2019). Patent law and pharmaceutical innovativeness. Intellectual Property Law Review.
